Gary Clark: Unfiltered

Janux Therapeutics is set to unveil key data for its cancer drug JANX007. The results could validate its precision platform and shake up the market.

Canacol Energy's cross-border bankruptcy is more than a corporate failure; it's a critical stress test for international law and Colombia's fragile energy supply.

Aquestive Therapeutics signals commercial readiness for its needle-free allergy film, setting up a high-stakes showdown in the multi-billion dollar market.

Enterprise Products Partners promotes internal candidate Michael ‘Tug’ Hanley to CCO, signaling stability and experience as the midstream giant navigates evolving energy markets and significant infrastructure investments.

A preliminary valuation of Oncotelic Therapeutics’ joint venture pipeline has reached $1.7 billion, spotlighting the potential of targeted nanomedicine and the growing appetite for innovative biotech assets in Hong Kong.

ENDRA Life Sciences’ thermoacoustic imaging technology aims to disrupt the liver disease diagnostics market with a cost-effective, accessible alternative to MRI. But can this financially challenged medtech firm deliver on its promise?

Controlled environment agriculture company expands retail footprint in Northeast, riding consumer demand for fresh, locally-sourced food while navigating a challenging financial landscape.

Plus Therapeutics secures national coverage with Humana, broadening access to CNSide®, a cutting-edge test for diagnosing and monitoring brain metastasis. This coverage, following UnitedHealthcare’s approval, signals a shift towards advanced diagnostics in cancer care.

Radiopharmaceutical developer Perspective Therapeutics is hitting the investor circuit, showcasing its alpha-emitting cancer therapies. With a crowded field and recent M&A activity, the company is seeking funding to advance its pipeline and scale manufacturing.

A joint venture between energy giants Enterprise and ExxonMobil expands NGL pipeline capacity out of the Permian Basin, signaling confidence in long-term growth and intensifying competition in the midstream sector.

SciSparc Ltd. and Clearmind Medicine Inc. are advancing a novel approach to treating depression with a non-hallucinogenic therapy. A recently filed patent application signals a commitment to innovative CNS treatments.

BeOne Medicines is poised to reshape hematological oncology with a diverse pipeline, highlighted by novel BTK degrader BGB-16673 and promising BCL2 inhibitor sonrotoclax. ASH 2025 presentations could be a key catalyst.

Medical device maker Baxter International increased its debt tender offer, suggesting financial strength despite recent earnings volatility and strategic shifts. A deeper look at the company's capital allocation.

Pharmaceutical giant Novartis is doubling down on US manufacturing with a $771M investment in North Carolina, signaling a broader trend of reshoring and bolstering domestic supply chains. The move promises jobs, economic growth, and advanced therapies.

Facing rating downgrades & operational headwinds, Baxter International is restructuring its debt. Is this a sign of strength or a necessary correction? We delve into the company’s financial strategy & industry outlook.

Biotech firm TG Therapeutics secures a spot on Deloitte’s Technology Fast 500, fueled by strong sales of its MS treatment, BRIUMVI. Analysts assess the company's trajectory and potential in a competitive market.

A new partnership aims to extend critical care beyond the hospital walls, leveraging FDA-cleared technology to improve outcomes for vulnerable infants and ease the burden on healthcare systems.

Medical imaging innovator Nanox Imaging acquires VasoHealthcare IT to accelerate US deployment of its AI-powered diagnostics. The deal signals a shift towards integrated solutions in a rapidly evolving market.

Small-cap biotech RenovoRx presents at an investor showcase amid Phase III trial progress and growing competition in targeted cancer therapies. Is the company’s TAMP platform poised for disruption?

Facing a competitive landscape and evolving business model, Vivos Therapeutics is doubling down on direct patient access through strategic acquisitions and expanding its sleep center network. Can this strategy fuel profitability?